Clinical trials: High-dose Chemotherapy
Acute Myeloid Leukemia (AML)
Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML)
This study will be conducted to assess the maximum tolerated dose (MTD) of panobinostat given 3 times a week (administered on weeks 2 and 3 of a 4 week cycle) in combination with induction chemotherapy (idarubicin and cytarabine)…
- Trial name
- NCT01242774
- Testing
- Panobinostat
- Where
- 10 sites in United States, Germany and 1 more
- Volunteers
- 46 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Gastric Cancer
Low-dose RAD001(Everolimus) Plus Cisplatin-HDFL Chemotherapy for the First-line Treatment of Advanced Gastric Cancer
The primary end-point of this study is to evaluate the objective response rates, and the secondary end-points are overall survival, progression-free survival and safety profile of low-dose RAD001 (everolimus) plus cisplatin and…
- Trial name
- NCT00632268
- Testing
- RAD001; Cisplatin; 5-FU; Leucovorin
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- National Taiwan University Hospital
Rectal Cancer
Phase II Trial of Preoperative High-dose-rate Endorectal Brachytherapy and FOLFOX Chemotherapy for Rectal Cancer
Standard treatment for rectum cancer is a pre-surgery course of external beam radiotherapy given with chemotherapy at the same time.
- Trial name
- HDRBT (NCT01659424)
- Testing
- High Dose Rate Endorectal Brachytherapy (HDR-ERBT)
- Where
- 2 sites in United States
- Sponsor
- Beth Israel Medical Center
Stage I Mantle Cell Lymphoma, Stage II Contiguous Mantle Cell Lymphoma
Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
This phase II trial studies how well ofatumumab in combination with cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and dexamethasone alternating with ofatumumab in combination with cytarabine and methotrexate…
- Conditions
- Stage I Mantle Cell Lymphoma, Stage II Contiguous Mantle Cell Lymphoma, Stage II Non-Contiguous Mantle Cell Lymphoma, Stage III Mantle Cell Lymphoma
- Trial name
- NCT01527149
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cytarabine
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- Roswell Park Cancer Institute
Breast Cancer, Leukemia
High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid Tumors
RATIONALE: Radiation therapy uses high-energy x-rays to damage cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Conditions
- Breast Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00060255
- Testing
- busulfan, carboplatin, carmustine
- Where
- United States
- Volunteers
- 451 people
- Sponsor
- Roswell Park Cancer Institute
Acute Myeloid Leukemia
A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies
This is an open-label, multi-center, Phase 1 study of PF-04449913 in Japanese patients. PF-04449913 will be administered orally as a single agent in patients with select advanced hematologic malignancies, or in combination with…
- Trial name
- NCT02038777
- Testing
- PF-04449913, Low dose ARA-C (LDAC), Daunorubicin
- Where
- 9 sites in Japan
- Volunteers
- 48 people
- Sponsor
- Pfizer
Hodgkin's Lymphoma
Bendamustine, Gemcitabine and Vinorelbine (BeGEV) as Induction Therapy in Relapsed/Refractory Hodgkin's Lymphoma Patients
Test of bendamustine in combination with gemcitabine and vinorelbine could contribute to a higher response rate with the reduction of toxic side effects
- Trial name
- NCT01884441
- Testing
- Bendamustine, Gemcitabine, Vinorelbine
- Where
- Italy
- Volunteers
- 59 people
- Sponsor
- Armando Santoro, MD
Rectal Cancer
Sphincter-preserving Surgery After Preoperative Treatment of Ultra-low Rectal Carcinoma
This phase III trial included patients with low rectal adenocarcinoma which initially required APR, with a mean clinical distance between the tumor inferior pole and the levator ani of 0.5 cm.
- Trial name
- GRECCAR1 (NCT00979680)
- Testing
- High-Dose radiotherapy, Chemo-radiotherapy
- Where
- 12 sites in France
- Volunteers
- 207 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Liver Lymphoma, Mantle Cell Lymphoma
A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma
This phase II trial compares three chemotherapy regimens consisting of bendamustine, rituximab, high dose cytarabine, and acalabrutinib and studies how well they work in treating patients with newly diagnosed mantle cell…
- Trial name
- NCT04115631
- Testing
- Acalabrutinib, Bendamustine, Bendamustine Hydrochloride
- Where
- 504 sites in United States
- Volunteers
- 360 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Lymphoma
Vaccine Therapy Following Chemotherapy & Peripheral Stem Cell Transplantation in Treating Non-Hodgkin's Lymphoma
RATIONALE: Vaccines made from a person's cancer cells may make the body build an immune response to kill cancer cells. Vaccine therapy may be an effective treatment for non-Hodgkin's lymphoma.
- Trial name
- NCT00006478
- Testing
- autologous tumor cell vaccine, keyhole limpet hemocyanin, sargramostim
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Nebraska
Primary Non-Hodgkin-Lymphoma, Refractory Non-Hodgkin-Lymphoma
A Study of Zevalin and Simultaneous Application of BEAM High-dose Chemotherapy Followed by Autologous Stem Cell Transplantation in Refractory and Relapsed Aggressive Non-Hodgkin Lymphomas
Phase II Study Concomitant High-Dose Radio-Immuno- and Chemotherapy with simultaneous application of Zevalin and BEAM followed by autologous peripheral stem cell transplantation in relapsed and refractory CD 20+ Non-Hodgkin's…
- Conditions
- Primary Non-Hodgkin-Lymphoma, Refractory Non-Hodgkin-Lymphoma, CD20+ Aggressive Non-Hodgkin's Lymphoma
- Trial name
- escZ-BEAM (NCT00521560)
- Testing
- Zevalin
- Where
- Germany
- Volunteers
- 28 people
- Sponsor
- Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH
Neuroblastoma
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Trial name
- NCT00004188
- Testing
- filgrastim, carboplatin, cisplatin
- Where
- 96 sites in United States, Canada
- Volunteers
- 495 people
- Sponsor
- Children's Oncology Group
Hodgkin Disease
High Dose Chemotherapy Followed By PBSC Rescue for HD
To evaluate the role of high dose chemotherapy with autologous hematopoietic cell transplantation in the treatment of Hodgkin's Disease.
- Trial name
- NCT00186251
- Testing
- high dose chemo then auto hematopoietic cell transplant
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Stanford University
Lymphoma
Combination Chemotherapy and Radiation Therapy in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed or Refractory Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00255723
- Testing
- carboplatin, etoposide, ifosfamide
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cancer
Ondansetron Plus Dexamethasone With or Without Metoclopramide as Antiemetic Prophylaxis After Receiving Cisplatin
The objective of this study is to assess the efficacy and tolerability of metoclopramide added to standard antiemetic regimen for prophylaxis of cisplatin-induced emesis.
- Trial name
- NCT01093690
- Testing
- metoclopramide
- Where
- Thailand
- Volunteers
- 162 people
- Sponsor
- Mahidol University
Fatigue, Leukemia
Effects of Periodized and Autoregulated Resistance Training in Haematological Cancer Patients During the Treatent.
Several clinical trials have demonstrated the positive impact of physical functioning and fatigue in patients who received training programs during the myeloablative chemotherapy with stem cell transplantation.
- Conditions
- Fatigue, Leukemia, Lymphoma, Physical Disability
- Trial name
- NCT04406285
- Testing
- Standard protocol Leukemia, Periodic Resistance Training Program Leukemia, Standard protocol Lymphoma
- Where
- 2 sites in Brazil
- Volunteers
- 66 people
- Sponsor
- Federal University of Health Science of Porto Alegre
Dual Use of Cigarettes and E-cigarettes
DOSE-UP: Dose Optimization for Smoking and E-Cigarette Use Pharmacotherapy
This randomized clinical trial evaluates the effectiveness of augmented-dose combination nicotine replacement therapy (NRT) versus standard-dose NRT and no-NRT control for cessation of dual combustible cigarette (CC) and…
- Trial name
- NCT07754578
- Testing
- Text- and web-based support, Nicotine Replacement Therapy (NRT, nicotine patch), Nicotine replacement therapy lozenge
- Where
- United States
- Volunteers
- 321 people
- Sponsor
- Medical University of South Carolina
Multiple Sclerosis
High Dose Chemo With Stem Cell Transplant as Treatment for Multiple Sclerosis That Failed Prior Treatment
The purpose of this study is to evaluate the toxicity and the effectiveness of high dose chemotherapy with HPC transplant Multiple Sclerosis that has failed at least two lines of therapy
- Trial name
- NCT01679041
- Testing
- Alemtuzumab, Fludarabine, Cyclophosphamide
- Where
- 3 sites in United States
- Volunteers
- 1 people
- Sponsor
- Seah Lim M.D.
Lymphoma
Y Zevalin and BEAM in Autologous Stem Cell Transplantation (ASCT) for Lymphoma
The goal of this clinical research study is to see if high-dose chemotherapy (BEAM) and rituximab, given together with the new drug 90Y Zevalin, followed by a transplant of blood or marrow stem cells is safe.
- Trial name
- NCT01538472
- Testing
- Y Zevalin, In Zevalin, Rituxan
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma and Plasma Cell Neoplasm
High-Dose Melphalan and a Second Stem Cell Transplant or Low-Dose Cyclophosphamide in Treating Patients With Relapsed Multiple Myeloma After Chemotherapy
RATIONALE: Giving chemotherapy and bortezomib before a peripheral stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them.
- Trial name
- NCT00747877
- Testing
- cyclophosphamide, melphalan, autologous hematopoietic stem cell transplantation
- Where
- 53 sites in United Kingdom
- Volunteers
- 460 people
- Sponsor
- Leeds Cancer Centre at St. James's University Hospital